(Q37107177)

18 August 2017

1 reference

title

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility (English)

1 reference

18 August 2017

1 reference

A R Hughes

1

1 reference

18 August 2017

W R Spreen

2

1 reference

18 August 2017

M Mosteller

3

1 reference

18 August 2017

L L Warren

4

1 reference

18 August 2017

E H Lai

5

1 reference

18 August 2017

C H Brothers

6

1 reference

18 August 2017

C Cox

7

1 reference

18 August 2017

A J Nelsen

8

1 reference

18 August 2017

S Hughes

9

1 reference

18 August 2017

D E Thorborn

10

1 reference

18 August 2017

B Stancil

11

1 reference

18 August 2017

S V Hetherington

12

1 reference

18 August 2017

D K Burns

13

1 reference

18 August 2017

A D Roses

14

1 reference

18 August 2017

11 March 2008

1 reference

The Pharmacogenomics Journal

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

6

1 reference

18 August 2017

365-374

1 reference

https://scigraph.springernature.com/pub.10.1038/tpj.2008.3

18 August 2017

0 references

cites work

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

New allele frequency database: http://www.allelefrequencies.net

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

HLA-B*5701 clinical testing: early experience in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.3

21 January 2018

Identifiers

DOI

10.1038/TPJ.2008.3

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference